Weekly Research Analysts’ Ratings Updates for Hims & Hers Health (HIMS)

A number of firms have modified their ratings and price targets on shares of Hims & Hers Health (NYSE: HIMS) recently:

• 11/20/2024 – Hims & Hers Health had its “buy” rating reaffirmed by analysts at TD Cowen. They now have a $28.00 price target on the stock.
• 11/14/2024 – Hims & Hers Health was downgraded by analysts at Bank of America Co. from a “buy” rating to an “underperform” rating. They now have a $18.00 price target on the stock, down previously from $32.00.
• 11/8/2024 – Hims & Hers Health had its price target raised by analysts at TD Cowen from $25.00 to $28.00. They now have a “buy” rating on the stock.
• 11/6/2024 – Hims & Hers Health had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $23.00 to $27.00. They now have a “hold” rating on the stock.
• 11/5/2024 – Hims & Hers Health had its “neutral” rating reaffirmed by analysts at Piper Sandler. They now have a $21.00 price target on the stock, up previously from $18.00.
• 11/5/2024 – Hims & Hers Health had its price target raised by analysts at Canaccord Genuity Group Inc. from $24.00 to $28.00. They now have a “buy” rating on the stock.
• 10/21/2024 – Hims & Hers Health had its price target raised by analysts at Bank of America Co. from $23.00 to $25.00. They now have a “buy” rating on the stock.
• 10/14/2024 – Hims & Hers Health had its price target raised by analysts at Bank of America Co. from $20.00 to $23.00. They now have a “buy” rating on the stock.

Hims & Hers Health Stock Performance

NYSE HIMS opened at $23.94 on Friday. Hims & Hers Health, Inc. has a one year low of $7.67 and a one year high of $30.44. The company’s 50 day moving average price is $20.37 and its 200 day moving average price is $19.12. The firm has a market capitalization of $5.23 billion, a price-to-earnings ratio of 54.40 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. During the same quarter in the prior year, the business earned ($0.04) EPS. Hims & Hers Health’s quarterly revenue was up 77.1% compared to the same quarter last year. Sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, Director Christiane Pendarvis sold 7,000 shares of the firm’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $15.15, for a total value of $106,050.00. Following the sale, the director now directly owns 23,917 shares in the company, valued at approximately $362,342.55. This trade represents a 22.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Soleil Boughton sold 2,345 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $14.65, for a total transaction of $34,354.25. Following the transaction, the insider now directly owns 159,796 shares of the company’s stock, valued at $2,341,011.40. The trade was a 1.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,056,183 shares of company stock valued at $21,501,682 over the last ninety days. Corporate insiders own 17.71% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

A number of hedge funds have recently made changes to their positions in HIMS. Robeco Institutional Asset Management B.V. acquired a new stake in Hims & Hers Health in the third quarter worth approximately $604,000. Carnegie Investment Counsel bought a new stake in Hims & Hers Health in the third quarter worth about $5,531,000. Royce & Associates LP lifted its holdings in Hims & Hers Health by 17.0% in the 3rd quarter. Royce & Associates LP now owns 341,000 shares of the company’s stock valued at $6,281,000 after acquiring an additional 49,500 shares during the last quarter. Versor Investments LP bought a new position in shares of Hims & Hers Health during the 3rd quarter valued at about $634,000. Finally, International Assets Investment Management LLC acquired a new position in shares of Hims & Hers Health in the 3rd quarter worth approximately $6,790,000. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.